Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance

Metabolism: Clinical and Experimental

Volumn 55, Issue 7, 2006, Pages 946-952

  Inoue, Ikuo ^a   Shinoda, Yuichi ^a   Nakano, Takanari ^a   Sassa, Masatoshi ^a   Goto, Sei ichi ^a   Awata, Takuya ^a   Komoda, Tsugikazu ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; COPPER SULFATE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DENSITY GRADIENT; DIET THERAPY; DISEASE PREDISPOSITION; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RISK REDUCTION; THERAPY EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ACARBOSE; ATHEROSCLEROSIS; FATTY ACIDS; GLUCOSE INTOLERANCE; HUMANS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; PPAR ALPHA; TRIGLYCERIDES;

EID: 33745117905     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.03.002     Document Type: Article

References (26)

1. de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., and Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22 (1999) 756-761
2. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., and Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
3. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation: Part I. Diagnosis and classification of diabetes mellitus (1999), World Health Organization, Geneva (Switzerland)
4. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., and Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1 (1980) 1373-1376
5. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
6. Chiasson J.L., Josse R.G., Leiter L.A., Mihic M., Nathan D.M., Palmason C., et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19 (1996) 1190-1193
7. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003) 486-494
8. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
9. Ogawa S., Takeuchi K., and Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab 6 (2004) 384-390
10. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48 (1999) 937-942
11. Izkhakov E., Meltzer E., and Rubinstein A. Pathogenesis and management of diabetic dyslipidemia. Treat Endocrinol 2 (2003) 231-245
12. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
13. Inoue I., Takahashi K., Kikuchi C., and Katayama S. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment. Diabetes Care 19 (1996) 1103-1107
14. Hirano T., Ito Y., and Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb 12 (2005) 67-72
15. Vuilleumier J.P., Keller H.E., Gysel D., and Hunziker F. Clinical chemical methods for the routine assessment of the vitamin status in human populations: Part I. The fat-soluble vitamins A and E, and beta-carotene. Int J Vitam Nutr Res 53 (1983) 265-272
16. Schlenk H., and Gellrman J.L. Esterification of fatty acids with dizomethane on a small scale. Anal Chem 32 (1960) 1412-1414
17. Kopprasch S., Pietzsch J., Kuhlisch E., Fuecker K., Temelkova-Kurktschiev T., Hanefeld M., et al. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 51 (2002) 3102-3106
18. Yoshino G., Hirano T., and Kazumi T. Treatment of small dense LDL. J Atheroscler Thromb 9 (2002) 266-275
19. Ceriello A., Bortolotti N., Motz E., Crescentini A., Lizzio S., Russo A., et al. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 21 (1998) 1529-1533
20. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
21. Delzenne N.M., and Kok N. Effects of fructans-type prebiotics on lipid metabolism. Am J Clin Nutr 73 (2001) 456S-458S
22. Wolever T.M., Radmard R., Chiasson J.L., Hunt J.A., Josse R.G., Palmason C., et al. One-year acarbose treatment raises fasting serum acetate in diabetic patients. Diabet Med 12 (1995) 164-172
23. Inoue I., Noji S., Shen M.Z., Takahashi K., and Katayama S. The peroxisome proliferator-activated receptor alpha (PPAR α) regulates the plasma thiobarbituric acid-reactive (TBARS) level. Biochem Biophys Res Commun 237 (1997) 606-610
24. Laaksonen D.E., Nyyssonen K., Niskanen L., Rissanen T.H., and Salonen J.T. Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids. Arch Intern Med 165 (2005) 193-199
25. Chang C.J., Hsieh R.H., Wang H.F., Chin M.Y., and Huang S.Y. Effects of glucose and α-tocopherol on low-density lipoprotein oxidation and glycation. Ann N Y Acad Sci 1042 (2005) 294-302
26. Andrulionyte L., Zacharova J., Chiasson J.L., and Laakso M. Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47 (2004) 2176-2184